Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

NEJM reports positive results for larotrectinib against TRK-fusion cancer

EurekAlert! - 22 Feb 2018 07:00
(University of Colorado Anschutz Medical Campus) 55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent.
Full Article at EurekAlert!

More Medical News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard